NEW YORK (GenomeWeb News) — Results of an ongoing collaboration between Lumera and the Harvard Institute of Proteomics have enabled the partners to try to use Lumera’s ProteomicProcessor biosensor to develop new diagnostics.
Since January, Harvard has served as a beta site for Lumera's platform. Researchers there have been trying to enable the ProteomicProcessor to analyze data from, their nucleic acid programmable protein array technology, also known as NAPPA.
Joshua LaBaer, director of the HIP, said in a statement todaty that "we now have a solid foundation on which to begin our development efforts. Among our first areas of investigation will be probing a family of 200 kinase proteins for their interaction with and among drug families relevant to cancer research."